Belimumab plus rituximab for primary membranous nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75.
- You have primary membranous nephropathy confirmed by a kidney biopsy within the last 5–7 years (depending on whether it’s new or relapsing).
- Your blood test is positive for anti-PLA2R (a specific antibody linked to primary membranous nephropathy).
- Your kidney function and protein in the urine meet study ranges (eGFR at least 30, and protein level in range while on maximum blood-pressure/RAAS medication).
- Your blood pressure is controlled while on maximum tolerated RAAS treatment.
- You have not had certain immune-suppressing medicines recently (including rituximab in the last 12 months, and steroids or other specific drugs in the last 30 days).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether rituximab (an immune-targeting medicine) plus cyclosporine (another immune medicine) can better control protein leakage in the urine for people with idiopathic membranous nephropathy. It may help reduce long-lasting kidney damage risk when standard treatments like ACE inhibitor or ARB don’t control the protein level.
This trial tests if an artificial intelligence tool can help doctors decide the best dose and timing of rituximab for people with a kidney condition called membranous nephropathy. It aims to improve treatment results and reduce side effects.
This trial looks at how people with primary membranous nephropathy (a kidney disease that causes swelling and protein in urine) do over time with their current treatment. It helps doctors understand which treatments work best, especially for those with severe protein loss.
This trial studies biological samples from patients with membranous nephropathy to understand why rituximab treatment sometimes stops working. It may help doctors find better ways to treat this kidney condition.
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
This trial studies how well rituximab works in primary membranous nephropathy (a kidney condition) either by itself or with corticosteroids (steroids). It aims to see which approach controls protein leakage in the urine and protects kidney function.
Hear when a new Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.